Literature DB >> 15128799

Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison.

Tazio Storni1, Martin F Bachmann.   

Abstract

The MHC class I pathway is usually fueled by endogenous Ags, while exogenous Ags reach the MHC class II pathway. Although exogenous epitopes may also enter the MHC class I pathway, quantification of the efficiency of the process has remained a difficult task. In an attempt of such a quantification, we directly compared the amount of exogenous virus-like particles required for induction of cytotoxic T cell responses by cross-priming with the amount of virus-like particles required for induction of Th cell responses by the conventional route of MHC class II loading as an internal standard. Surprisingly, we found that cross-presentation of peptides derived from exogenous Ags on MHC class I molecules is of only marginally lower efficiency ( approximately 1- to 10-fold) than the classical MHC class II pathway in vitro and in vivo. Thus, Ag quantities required for cross-presentation and cross-priming are similar to those required for fueling the MHC class II pathway.

Mesh:

Substances:

Year:  2004        PMID: 15128799     DOI: 10.4049/jimmunol.172.10.6129

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.

Authors:  Martin F Bachmann; Gary T Jennings
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

2.  Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies.

Authors:  Christiane Ruedl; Katrin Schwarz; Andrea Jegerlehner; Tazio Storni; Vania Manolova; Martin F Bachmann
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells.

Authors:  Denis Leclerc; Diane Beauseigle; Jérome Denis; Hélène Morin; Christine Paré; Alain Lamarre; Réjean Lapointe
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

4.  Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches.

Authors:  Simone Grasso; Luca Santi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-07-06

Review 5.  Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.

Authors:  T W H Flinsenberg; E B Compeer; J J Boelens; M Boes
Journal:  Clin Exp Immunol       Date:  2011-05-11       Impact factor: 4.330

6.  Exploring the immunopotentiation of Chinese yam polysaccharide poly(lactic-co-glycolic acid) nanoparticles in an ovalbumin vaccine formulation in vivo.

Authors:  Li Luo; Tao Qin; Yifan Huang; Sisi Zheng; Ruonan Bo; Zhenguang Liu; Jie Xing; Yuanliang Hu; Jiaguo Liu; Deyun Wang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Construction and characterization of insect cell-derived influenza VLP: cell binding, fusion, and EGFP incorporation.

Authors:  Yi-Shin Pan; Hung-Ju Wei; Chung-Chieh Chang; Chung-Hung Lin; Ting-Shyang Wei; Suh-Chin Wu; Ding-Kwo Chang
Journal:  J Biomed Biotechnol       Date:  2010-12-09

8.  Absence of cross-presenting cells in the salivary gland and viral immune evasion confine cytomegalovirus immune control to effector CD4 T cells.

Authors:  Senta M Walton; Sanja Mandaric; Nicole Torti; Albert Zimmermann; Hartmut Hengel; Annette Oxenius
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

9.  Immune response to a potyvirus with exposed amino groups available for chemical conjugation.

Authors:  Carlos Alberto Manuel-Cabrera; Ana Márquez-Aguirre; Hernández-Gutiérrez Rodolfo; Pablo César Ortiz-Lazareno; Gabriela Chavez-Calvillo; Mauricio Carrillo-Tripp; Laura Silva-Rosales; Abel Gutiérrez-Ortega
Journal:  Virol J       Date:  2012-03-27       Impact factor: 4.099

10.  Advanced antigen delivery of murine survivin: chimeric virus-like particles in cancer vaccine research.

Authors:  Thomas Schumacher; Claus Ruehland; Christine Schultheiss; Marc Brinkman; Franz Roedel; Christian O A Reiser; Juergen Hess; Christoph Reichel
Journal:  Int J Biomed Sci       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.